Amylyx Pharmaceuticals, Inc.

AMLX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$225,178$58,085$59,764$77,391
Short-Term Investments$118,812$122,741$144,304$99,110
Receivables$232$203$300$447
Inventory$0$0$0$0
Other Curr. Assets$9,161$5,861$11,776$12,484
Total Curr. Assets$353,383$186,890$216,144$189,432
Property Plant & Equip (Net)$5,875$6,257$2,072$2,732
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$983$1,451$0$0
Tax Assets$0$0$0$0
Other NC Assets$2,500$0$1,460$1,470
Total NC Assets$9,358$7,708$3,532$4,202
Other Assets$0$0$0$0
Total Assets$362,741$194,598$219,676$193,634
Liabilities
Payables$5,339$3,294$4,810$2,939
Short-Term Debt$981$665$1,055$1,518
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$19,471$17,465$12,067$23,949
Total Curr. Liab.$25,791$21,424$17,932$28,406
LT Debt$4,954$5,297$327$463
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$4,954$5,297$327$463
Other Liabilities$0$0$0$0
Cap. Leases$4,954$5,962$1,382$1,981
Total Liabilities$30,745$26,721$18,259$28,869
Equity
Pref Stock$0$0$0$0
Common Stock$11$9$9$7
Retained Earnings-$718,428-$684,042-$642,599-$606,692
AOCI$815$551$0-$92
Other Equity$1,049,598$851,359$844,007$771,542
Total Equity$331,996$167,877$201,417$164,765
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$362,741$194,598$219,676$193,634
Net Debt-$219,243-$52,123-$58,382-$75,410